patients have been prescribed HUMIRA for plaque psoriasis since its FDA approval in 2008.3,4
HUMIRA clinical data includes dramatic skin clearance at 16 weeks for most patients and a well-studied safety profile in moderate to severe Ps.1,6-10
HUMIRA clinical data includes inhibition of radiographic progression at week 48 vs placebo at week 24 and improvement of signs and symptoms at week 12 in many patients.1
In 2019, over
of National Commercial, Medicare Part D, and Medicaid patients have access to HUMIRA as a preferred, first-line† targeted immunomodulator (TIM) on formulary.11
†Formulary Definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.
Resources to help your patients start and stay on track with their treatment plan.
Only HUMIRA is FDA-approved to provide clinically meaningful improvement in moderate to severe HS.1,12